Cell-penetrating peptides in protein mimicry and cancer therapeutics by Zorko, Matjaž et al.
Advanced Drug Delivery Reviews 180 (2022) 114044Contents lists available at ScienceDirect
Advanced Drug Delivery Reviews
journal homepage: www.elsevier .com/ locate/adrCell-penetrating peptides in protein mimicry and cancer therapeuticshttps://doi.org/10.1016/j.addr.2021.114044
0169-409X/ 2021 The Authors. Published by Elsevier B.V.
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
⇑ Corresponding author at: University of Stockholm, Department of Biochemistry and Biophysics, Svante Arrhenius väg 16, 106 91 Stockholm, Sweden.
E-mail addresses: S.Jones4@wlv.ac.uk (S. Jones), ulo.langel@dbb.su.se (Ü. Langel).Matjaž Zorko a, Sarah Jones b, Ülo Langel c,d,⇑
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Cancer therapy and diagnostics
Intracellular signaling
Cancer cell targetinga b s t r a c t
Extensive research has been undertaken in the pursuit of anticancer therapeutics. Many anticancer drugs
require specificity of delivery to cancer cells, whilst sparing healthy tissue. Cell-penetrating peptides
(CPPs), now well established as facilitators of intracellular delivery, have in recent years advanced to
incorporate target specificity and thus possess great potential for the targeted delivery of anticancer car-
goes. Though none have yet been approved for clinical use, this novel technology has already entered
clinical trials. In this review we present CPPs, discuss their classification, mechanisms of cargo internal-
ization and highlight strategies for conjugation to anticancer moieties including their incorporation into
therapeutic proteins. As the mainstay of this review, strategies to build specificity into tumor targeting
CPP constructs through exploitation of the tumor microenvironment and the use of tumor homing pep-
tides are discussed, whilst acknowledging the extensive contribution made by CPP constructs to target
specific protein–protein interactions integral to intracellular signaling pathways associated with tumor
cell survival and progression. Finally, antibody/antigen CPP conjugates and their potential roles in cancer
immunotherapy and diagnostics are considered. In summary, this review aims to harness the potential of
CPP-aided drug delivery for future cancer therapies and diagnostics whilst highlighting some of the most
recent achievements in selective delivery of anticancer drugs, including cytostatic drugs, to a range of
tumor cells both in vitro and in vivo.
 2021 The Authors. Published by Elsevier B.V. This is an open access articleunder the CCBY license (http://
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Despite extensive research and generations of therapeutic
modalities, cancer still represents a global health burden that
was estimated to have caused ten million deaths in 2018 [1]. Can-
cer is usually treated by a combination of surgery, chemotherapy
and radiotherapy, all of which are accompanied by serious side
effects. An additional problem is the development of drug resis-
tance by cancer cells [2]. A serious obstacle in the treatment of this
disease is a low permeability of the cell membrane to therapeutics.
All these call for more effective drug delivery systems. One hope
for improved control of the disease is the use of the cell-
penetrating peptides (CPPs) that can aid in the targeted delivery
of anticancer drugs to tumor tissue whilst normal healthy tissue
remains unharmed. In this review we present different CPPs and
their potential use in cancer treatment. Although the discovery
and use of CPPs spans more than 30 years, they have yet to enter
clinical practice. Altogether, around 30 CPPs are in clinical trials,
but only a few have entered Phase III; for oncological treatments
only one has reached Phase I clinical trials and no CPP or CPP-
drug construct has been approved by the FDA for cancer thus far
[3]. In this review we present recent research and the enormous
potential offered by CPPs in the treatment of cancer.2. What is a cell-penetrating peptide (CPP)?
The short definition of a CPP is: CPPs are up to 40 amino acids
long peptides, with the ability to gain access to the cell interior
by means of different mechanisms, and/or with the capacity to pro-
mote intracellular effects by themselves or by the delivered bioac-
tive cargoes. Almost the same definition appeared 20 years ago in
the first book on CPPs [4] and in many papers on CPPs thereafter
[5]. A great number of CPPs have been identified in the past
30 years. Analyses of their structures and properties indicate that
the only common feature of CPPs is their ability to cross biological
membranes and carry cargos inside cells. The name cell-
penetrating peptide and its abbreviation CPP appeared first in
1998 [6] and was soon generally accepted. Other names for CPPs
found in the literature include; protein transduction domains (for
CPPs generated from protein sequences that enable protein to
enter the cell), membrane transduction peptides, Trojan horse pep-
tides, bioportides (intrinsically bioactive CPPs designed to target
and modulate intracellular protein–protein interactions without
the use of a cargo) and some others.
In the year 1988 a paper was published describing the first
transfer of a functional protein (horseradish peroxidase) into the
cell by using a protein named trans activator of transcription
(Tat-protein), the latter being derived from the human immunod-
eficiency virus [7]. It soon became evident that effective intracellu-
lar translocation did not require the complete Tat-protein. The
minimal domain of the Tat-protein needed for cellular-
internalization of the cargo comprised of 11, mainly cationic,
amino acids [8]. In this way the first CPP simply called Tat was2
born, followed by a 16 amino acid long peptide from the homeobox
Antennapedia transcription factor of Drosophila melanogaster [9],
later called penetratin. From there on, the number of CPPs
increased enormously, the precise number is still unknown. The
freely accessible database of CPPs (https://webs.iiitd.edu.in/
raghava/cppsite/) now (fall 2021) contains 1855 entries with the
following information: peptide sequence, nature of the peptide,
chemical modifications, experimental validation techniques, struc-
ture of the peptide and types of cargo delivered.2.1. Classification of CPPs
Traditionally, the classification of CPPs is based on their physic-
ochemical properties, their origins, or other characteristic features
[10]. Physicochemical properties of CPPs arise from CPP structure.
In this respect CPPs are usually divided into three groups: cationic,
amphipathic and hydrophobic. Being composed of mostly posi-
tively charged amino acids, mainly Arg (R) and Lys (K), cationic
CPPs are positively charged at physiological pH. Examples of catio-
nic CPPs are Tat (GRKKRRQRRRPQ, [8], and poly-arginine (Arg)8-10
(cf. Arg8 RRRRRRR) [11]. Amphipathic CPPs are constructed of a
suitable combination of hydrophilic and hydrophobic amino acids,
where amphipathicity is due to the sequence or is achieved after
folding of the CPP into an a-helix with a hydrophilic and a
hydrophobic face: an example is MAP, KLALKLALKALKAALKLA,
[12]. Hydrophobic CPPs are made of hydrophobic amino acids
but some hydrophilic amino acids must also be included, other-
wise the CPP would become insoluble in bodily fluids and be
retained in the hydrophobic core of the lipid bilayer when passing
through the cell membrane. An example is Pep-7, a synthetic
hydrophobic a-helix, SDLWEMMMVSLACQY, [13]. It should be
stressed here that some anionic peptides have also been shown
to penetrate into cells [14].
In accordance with their origins, CPPs are usually also divided
into three groups: protein-derived, chimeric and synthetic.
Protein-derived CPPs represent part of the natural protein struc-
ture that can transfer across the membrane. The oldest example
is Tat. Chimeric CPPs are composed of two peptides from different
origins. An example is Transportan (abbreviated TP, GWTLNSA-
GYLLGKINLKALAKISIL [6] which is composed of part of the hor-
mone galanin followed by the sequence of wasp venom
mastoparan. Synthetic CPPs are artificially designed, an example
is MAP (see sequence above).
Another level of classification is of particular clinical impor-
tance. In this classification, CPPs are divided into cell-specific and
non-cell-specific peptides. As their names clearly indicate, cell-
specific CPPs are able to deliver cargos into specific cells, whilst
non-cell-specific CPPs are not selective.
Because of the great number of very different CPPs, all levels of
CPP classification are very broad and usually give overlapping
results. In order to classify CPPs more precisely, taking into account
as many properties as possible, a new approach was adopted.
Classes of CPPs were grouped into pairs to cover eight levels of
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properties were presented. This approach was recently published
[15] and is as follows.
1. Protein-derived vs. designed
2. Classified by physico-chemical properties vs. classified by struc-
tural properties
3. Predicted vs. random
4. Linear vs. cyclic
5. Protein mimics vs. cargo delivery vectors
6. Nonspecific vs. targeted
7. ‘‘Direct” translocators vs. endocytosis enhancers
8. ‘‘Non-toxic” vs. antimicrobial
Clearly, many CPPs can simultaneously belong to several sub-
classes more details in [15]. This classification system is open for
additional discussions and changes.2.2. Cell internalization of CPPs (with cargo)
There are two main routes of CPPs with or without cargo by
which they can transfer through cell and organelle membranes:
direct penetration or one of several endocytic mechanisms. How-
ever, detailed mechanisms of CPP internalization are still not clear.
It seems that direct internalization is related to the destabilization
of the membrane and is particularly true for the cationic CPPs that
include lysine or arginine in their structure, for instance poly-
arginines [16,17]. Destabilization of the membrane can be initiated
by the accumulation of positively charged CPPs on the negatively
charged membrane surface, by attracting water molecules that
bind to charged amino acids of CPPs in the hydrophobic core of
the lipid bilayer [18], or by inducing transfer pores in the mem-
brane [19]. Curvature of the membrane and the depletion of the
amount of cholesterol in the membrane could further destabilize
the lipid bilayer thereby assisting the peptide to traverse the mem-
brane. For penetratin it was [20] proposed that spontaneous direct
translocation of the membrane occurs through formation of an
inverted micelle. Later [21] it was suggested that this mechanism
could also be utilized by several other cationic CPPs.
Another internalizationmechanism, which seems to be themain
route of entry for many CPPs with or without cargo, encompasses
different mechanisms of energy-dependent endocytosis, including
clathrin- and caveolin-mediated endocytosis, other receptor-
dependent endocytotic mechanisms, macropinocytosis, and possi-
bly other endocytic routes [22]. It seems that for cancer tissue the
most important route of internalization is macropinocytosis [23].
CPP (and cargo) normally accumulate in endosomal vesicles which
further mature into lysosomes where CPP and cargo are usually
degraded. Therefore, fast endosomal escape is a prerequisite for
the effective delivery of a cargo into the cytosol. Different strategies
were developed to enhance endosomal escape of CPP and cargo so
as to achieve more effective delivery. A review of these strategies
was recently published [24]. It should be stressed here that many
CPPs in the delivery of their cargo seem to be able to use both direct
and endocytic routes of internalization. It was suggested for
instance that Tat and penetratin can cross the membrane passively
only at low concentrations while at higher concentrations they use
both direct and endocytic routes [25]; interestingly, another group
has obtained entirely opposite results [26].3. Strategies for CPP conjugation to anticancer cargos
Anticancer molecules or complexes should enter the tumor cells
in order to act effectively. Internalization of anticancer drugs can
be markedly improved by coupling to a CPP.3
3.1. Cell-penetrating sequences in protein structures
Concerning proteins as anticancer drugs, some possess intrinsic
cell-penetrant properties, the so-called shuttling proteins. In some
cases, cellular penetration of proteins can be induced or enhanced
by incorporating a cell-penetration promoting sequence into the
structure of the protein. In addition to the Tat-protein, several
other proteins with transducing capabilities have been identified,
for instance, ANTP [27], HoxB4 [28], the herpes simplex virus type
1 VP22 transcription factor [29,30], OCT 4 that can enter the cell
and influence its programming [31], engrailed-2 (En-2), that is able
to penetrate cells and function as a transcription factor [32],
Engrailed 1, EN1 [33], Knotted-1 [34], Otx2 [35], Pax4 involved
in vertebrate organogenesis [36], the protein NeuroD/BETA2 [37],
protein–ligand complex neocarzinostatin, NCS [38], Omomyc
mini-protein, a Myc inhibitor [39], human papillomavirus minor
capsid protein L2 [40], to name but a few.
Finding CPP sequences can be a matter of reasonable guess-
work, or it can be generated by computerized prediction algo-
rithms [41–43]. Successful incorporation of CPP sequences into
proteins to promote their effective penetration into cells has been
achieved in some cases. It is also of paramount importance not to
disturb protein structure and function when introducing cell-
penetrant sequences. Therefore, it is usual practice to include
cell-penetrating sequences into open loops [44] of anticancer pro-
teins or as flanking CPP sequences at the C- or N-termini of pro-
teins. Moreover, when CPPs are incorporated into protein loops,
the propensity for cellular penetration is enhanced when the CPP
is constrained by the protein into a cyclic structure [45,46]. Genetic
engineering is clearly of great use, permitting the expression of
such constructs in one step. However, in most cases, anticancer
molecules are coupled to CPPs.
3.2. Coupling of anticancer molecules to CPPs
Cargos can be conjugated to CPPs in different ways – by cova-
lent coupling or by forming a complex, using multiple weak inter-
actions [47]. When covalent attachment of a cargo to a CPP is
employed, the cargo can be attached directly to the CPP or via a
suitable spacer where the cargo is tethered to the CPP through a
cleavable bond, such as hydrazine or disulfide [48]. It has long been
known that inclusion of cargos usually decreases the rate and effi-
ciency of translocation, an observation that is dependent upon the
nature of the cargo and its dimensions [49]. However, in some
cases it was observed that penetration efficiency can be increased
if the CPP is designed to self-assemble into spherical micelles thus
locally increasing its local interface density [50] or when the flex-
ible spacer is replaced by a constrained cyclic spacer [51]. Spacers
can also contribute to site-specific intracellular delivery of the
cargo and thus ensure selectivity towards cancer tissue [52]. Selec-
tivity or targeting is discussed in the next section in more detail.
Oligonucleotides can also be covalently attached to a CPP, either
to a 30 or 50 site via a suitable linker, which may or may not be
cleavable – a recent review of these attachments to siRNA is avail-
able [53]. When a cargo is non-covalently conjugated to a CPP, the
conjugation is governed by multiple electrostatic and hydrophobic
interactions between the CPP and its cargo. An interesting example
is to couple a modified negatively charged leucine zipper to the
CPP and a modified positively charged leucine zipper to the cargo
molecule, or vice versa; zippers can electrostatically bind to each
other thus coupling the CPP to the cargo [54]. Non-covalent cou-
pling of CPPs to cargos usually results in the formation of complex
nanoparticles – for a comprehensive review see [55].
Extensive research has recently focused on decorating lipo-
somes and nanoparticles with CPPs, thus enhancing their penetra-
tive propensity and propounding their use as viable delivery
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we list only four [56–59]. Although these constructs and CPPs in
general have not been accepted for clinical use, their potential clin-
ical applications are under intensive testing and discussion. Three
of the most recent reviews are listed here [60–62]. Of equal impor-
tance, is the establishment of the precise intracellular loci of the
delivered cargo. Several methods have been developed to locate
the delivered cargo within subcellular compartments and tissues.
A recent review of these methods has been published by [63].
The reticuloendothelial system (RES) plays a pivotal role in host
defence through clearance of foreign material in the circulation
and tissues. Thus, a concern and challenge to the therapeutic utility
of cationic CPP constructs is premature removal by immune cells of
the RES, leading to a reduced half-life and lack of efficacy in vivo
and this is particularly exemplified by the use of large cationic lipo-
somal constructs used for the delivery of oligonucleotides [64].
Moreover, it has been suggested that the employment of neutral
or acidic CPPs may lead to a more favourable in vivo pharmacoki-
netic outcome [65].
Conversely, the inclusion of CPP technology has been shown to
improve the therapeutic potential of cationic liposomes and their
use in cancer therapy. Nakamura et al. [66] demonstrated the
superiority of R8-modified liposomes in vaccinology. The inclusion
of octaarginine (R8) into OVA containing liposomes enhanced anti-
gen presentation and antigen-specific cytotoxic lymphocyte
responses compared to cationic liposomes and pH-sensitive lipo-
somes, whilst significantly suppressing tumour growth in vivo.
Clearly, premature elimination of cationic CPP constructs by the
RES poses a future challenge for translation into the clinical setting,
whilst further clarification of the role of RES in in vivo CPP metabo-
lism is required.
Antibody delivery and immune detection in cancer, Section 4.3.,
provides further evidence, including in vivo experiments, of CPP
constructs, as opposed to being destroyed by the immune system,
being used to enhance tumor-specific immune responses.4. Strategies for targeting different tumor cells
Initially it seemed that CPPs, frequently coupled to fluorescent
dyes, could enter non-selectively into practically all genres of cell
lines, which was regarded as a great achievement. However, this
unique feature was undesirable when considering CPPs as drug
delivery molecules. In fighting numerous disease states, specific
delivery into cells, tissues, organs and organelles is mandatory.
Therefore, much effort has focused on the improvement of CPPs
to specifically target diseased tissue. The most studied disease isFig. 1. Building specificity into tumor targeting CPP constructs. (A) Enzyme activatable C
tumor microenvironment. Penetrative ability determined by cationic charge is shielded
specific linker liberates the CPP and cargo and penetrative propensity is restored. (B) p
functionalized PEGylated micelles carrying doxorubicin (DOX) renders the construct
microenvironment, cationic charge is restored and Tat becomes functionalized. Functiona
nuclear delivery [233]. (ii) The penetrative propensity of pH (low) Insertion Peptides (pH
Protonation of these residues within the low pH of the tumor microenvironment renders
a transmembrane helix within the lipid bilayer of the plasma membrane [234]. pHLIP
potential for future targeting of pancreatic cancer [68]. (iii) pH-responsive and PEG-shedd
the specific delivery of Irinotecan to colon cancer. Demonstrating low toxicity in the bloo
a CPP (yellow), a targeting peptide specific for angiogenic neovasculature (red) and
degradation domain)-caspase 3 fusion protein degrades in the microenvironment of norm
(D) Specificity for tumor cells, vasculature or lymphatics can be achieved through selec
studies regarding the utility of tumor homing peptides to facilitate therapeutic cargo del
are tumor homing peptides which demonstrate cell penetrating properties. Derived fro
(designated as green) whilst sparing normal lymphatic tissue [235]. Similarly, the 9 amin
tumor penetrating peptide iRGD, distributes more extensively into extravascular tumo
therapeutics such as doxorubicin (DOX), paclitaxel (PAC) and trastuzumab (TRmAB) [87,2
peptide gHo and the CPP pVEC, crosses the BBB to selectively accumulate within xenogra
construction of this figure. (For interpretation of the references to colour in this figure l
4
cancer. To ensure their survival and progression, tumor cells create
a unique microenvironment within their surrounding milieu which
is typified by a decreased pH, hypoxia or exclusive expression of
specific proteins on the outer surface of tumor cells. These distinc-
tive features were used to invent strategies to develop targeted
CPPs that internalize into specific tumor cells whilst sparing
healthy tissue. Universal systematic presentation of such strategies
has not been generally accepted. An additional problem is that the
targeting strategies are overlapping, see Fig. 1.
4.1. pH sensitive methods
It is known that cancer cells require a high amount of energy
frequently supplied by an increased level of anaerobic glycolysis.
This is accompanied by a high production of lactate and protons.
Therefore, the surrounding tumor microenvironment is usually
acidic, which assists in tumor growth, metastasis and drug resis-
tance. This can be used to target tumor tissue by pH-responsive
peptides which can be coupled to a CPP and an anticancer cargo
or to a nanocarrier [67]. Of particular interest are so called pH
low insertion peptides (pHLIPs), introduced and presented by
Han and coauthors [68], see Fig. 1B. Depending on the pH of their
environment they can exist in different states. At lower pH condi-
tions, their acidic amino acid residues bind protons losing their
negative charge, thereby enabling pHLIPs to penetrate deeper into
the membrane, which subsequently promotes their cell
internalization.
4.2. Hypoxia responding approaches
Hypoxia is another characteristic of the tumor microenviron-
ment that has been used for targeting cancer tissue. Treating tissue
with Tat fused to a fragment of the oxygen-dependent degradation
domain of hypoxia-inducible factor-1a protein, showed that such
fusion constructs are stable in hypoxic environments and can pen-
etrate cancer cells, whilst degradation occurs in the local microen-
vironment of normal cells, thus rendering the latter unaffected
[69]. This approach is frequently combined with others and can
be used with a pH sensitive CPP, for instance [70], see Fig. 1C.
4.3. Enzyme-triggering activation
The development of activable CPPs (aCPPs) has been another
approach used for target-specific delivery, particularly to cancer
tissue, see Fig. 1A. Membranes of tumor cells are extracellularly
coated with different enzymes that are not expressed by healthyPP constructs exploit the expression of matrix metalloproteases (MMPs) within the
outside of the tumor microenvironment by anionic residues. Cleavage of an MMP-
H-activatable constructs including CPPs. (i) Amidization of the Lys residues of Tat-
penetratively inert in the blood stream. On reaching the low pH of the tumor
lization is further restored in the acidic conditions of lysosomes enabling escape and
LIPs) is lost owing to the negative charges provided by Asp, Glu and the C-terminus.
pHLIPs more hydrophobic to assist intracellular cargo delivery through formation of
-modified gemcitabine (GEM)-coated magnetic nanoparticles have demonstrated
ing targeting peptide nanoparticles are multivalent constructs showing potential for
d and non-tumor cells, PEG shedding in the acidic tumor microenvironment exposes
mitochondria-targeting peptide (blue) [67]. (C) The Tat-ODD (oxygen-dependent
al cells but stabilizes in the hypoxic conditions of the tumor microenvironment [69].
tion of high affinity ligands using phage display technologies. There is a wealth of
ivery. A mere fraction is represented above. Of particular significance to this review
m in vivo phage display, LyP-1 accumulates specifically within tumor lymphatics
o- acid cyclic analogue of the tumor vasculature integrin binding RGD peptide, the
r tissue and increases tumor vascular and tissue permeability to co-administered
36]. The glioma targeting delivery vector gHoPe2, consisting of the glioma targeting
ft tumor tissue [106]. Servier Medical Art: https://smart.servier.com was used in the
egend, the reader is referred to the web version of this article.)
"
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which are endopeptidases capable of degrading protein structures
in the extracellular matrix and are important for tumor invasion
and metastasis. The term aCPPs was first used by the R.Tsien’s
group [71]. They blocked positively charged polyarginine CPPs
through intramolecular shielding with a negatively charged pep-
tide domain. The CPP and shielding domain are connected by a
suitable peptide linker that can be cleaved by metalloproteases.
In this way, the cell-penetrating ability of the CPP is reactivated
by protons in the tumor cell microenvironment and the aCPP can
deliver the anticancer cargo exclusively into tumor cells, whilst
the construct is unable to penetrate normal cells. This approach,
in which the circulating CPP is not active in the bloodstream, but
becomes activated at the intended site of cargo delivery, may also
be classed as a prodrug mechanism. Furthermore, this technology
has demonstrated potential utility for the detection of tumor cells
and the delineation of the margin between tumor and normal tis-
sue [72], besides its great potential for specific delivery of antitu-
mor therapeutics [73]. Such tumor-oriented carriers could be
further optimized, for instance with photosensitive CPPs that are
activated after illumination by UV-light [74]. aCPPs have been used
for the selective delivery of drugs into tumor cells and as such dox-
orubicin [75,76], pDNA [48,77,78], siRNA [79] and antibodies [80]
have been delivered. This strategy has already proven successful
for tumor imaging, more than 15 years ago [71] and more recently,
for tumor gene therapy delivering plasmid DNA [81] and for the
inhibition of tumor growth [82].
4.4. Tumor homing ligands
Tumor targeting ligands require a suitable targeting molecule
on the surface of the cancer cell and a corresponding high affinity
ligand which specifically binds to the targeted molecule. In general,
affinity targeting is aimed towards recognition of cancer cell recep-
tors by antibodies or their fragments, proteins, peptides, carbohy-
drates, aptamers or small receptor ligands that are attached to
CPPs, see Fig. 1D. The interactions between receptors and CPP
bound ligands could be applied to targeting cancer tissue since
cancer cells express a different repertoire of receptors to that of
normal tissue. An important step in this direction has been the syn-
thesis of cancer cell penetrating peptides and specific tumor hom-
ing peptides [83–88]. Moreover, several classical cell surface
receptors [89–93], specific localization sequences, for instance
NLS [94–96], or mitochondrial SS-peptides [97,98] and mtCPP1
[99], can be used for targeting.
A number of tumor tissue homing peptides have been identi-
fied. Some examples are iRGD (CRGDKGPDC) that incorporates an
integrin-binding RGD motif for recognition of the tumor endothe-
lium [100], the CPP YTA2 which is coupled to cytostatic methotrex-
ate (MTX) [101] and the cyclic peptide cCPGPEGAGC (PEGA) which
becomes penetrant when bound to pVEC and functions as a breast
tumor homing peptide in mice [102]. More complex approaches
include nanoparticles and anticancer agent-loaded liposomes.
Examples include silver nanoparticles (AgNPs) decorated with
either the cancer cell penetrating peptide RPARPAR which is recog-
nized by the tumor-cell receptor NRP1, or the cancer cell homing
peptide GKRK, recognized by the tumor-cell receptor p32 [103].
These constructs were used to target PPC1 prostate cancer and
melanoma cells in vitro. More complex liposomal delivery systems
include, liposomes loaded with doxorubicin, dually labelled and
surface-anchored with the CCK8 tumor targeting peptide and the
CPP R8 [104].
Other tissue specific targeting systems can be used to target
tumor cells. The blood–brain-barrier (BBB) is particularly difficult
to penetrate, but several brain targeting homing peptides have
been developed [105] and glioma targeting CPPs have been devel-6
oped through the construction of chimeric peptides consisting of
glioma targeting sequences and CPPs, for instance the homing pep-
tide gHo and the CPP pVec, resulting in the tumor-targeted deliv-
ery vector gHoPe2 [106]. A further example includes the
transferrin receptor-targeting peptide linked to myristoylated
transportan (myr-TP-Tf) [107]. This construct encapsulates siRNA
and carries it across the BBB into the brain to enter not only glioma
cells, but also murine neurons and astrocytes, whereupon it
induces gene silencing. The amphipathic helical peptide NF55 has
recently been used in vivo [108,109] and condenses plasmid DNA
(pDNA) into stable nanoparticles which enter different tumor mice
models including intracranial glioblastoma; pDNA can be con-
structed in such a way as to reduce tumor growth. For the
improved survival of mice bearing glioma, a new nanoparticle
delivery system (AsTNP) was constructed by coupling the AS1411
aptamer, which targets glioma and the TGN peptide, which pro-
motes passage through the BBB [110]. Besides brain tissue, cardiac
tissue can also be targeted by coupling a 30-nucleotide long RNA
fragment (RNA Apt30) to a CPP [91]. This construct, called phos-
pholamban, can transfer RNA into rat cardiomyocytes; by choosing
suitable RNA it can further improve calcium ion transients and
myocyte contraction.
It is obvious that several reports on finding novel selective
delivery vectors with selectivity towards cancer cells lack the
appropriate controls of uptake by ‘‘normal” cells; likely such con-
trols are not easily available. We suggest that the vector (CPP)
selectivity is best described in the reports describing the in vivo
delivery to tumor cells. In Table 1, we exemplify few available
reports on in vivo tumor delivery by CPP assistance, specifically
on nuclear and mitochondrial specificity. Additionally, a few exam-
ples are available of different CPP-assisted plasmid expressions in
tumors in vivo and are exemplified by some of our own reports
[81,111,112]. Every one of such reports is also an example of the
nuclear delivery of the plasmid.
It is obvious that several reports on finding novel selective
delivery vectors with selectivity towards cancer cells lack the
appropriate controls of uptake by ‘‘normal” cells; likely such con-
trols are not easily available. We suggest that the vector (CPP)
selectivity is best described in the reports describing the in vivo
delivery to tumor cells. In Table 1, we exemplify some of the many
in vivo reports of CPP-mediated tumor delivery, but with the addi-
tional feature of intracellular target specificity towards the nucleus
and mitochondria.
Targeting tumor cells is one of the challenges for development
of CPP-based therapeutic and diagnostic strategies, especially
in vivo. We believe that the described approaches have successfully
laid the foundations for targeted delivery systems with potential
clinical utility once the final hurdles have been surmounted.5. Modulating protein–protein interaction by CPPs that
internalize proteins, mimicking peptides or oligonucleotides, or
through internalizing shuttling proteins
There is no doubt that protein–protein interactions play an
important role in cancer. In this review we use a broad definition
of mimicry that includes promoting and preventing any protein–
protein interaction in cancer cells that disturbs cancer develop-
ment or contributes to tumor reduction by the action of small pep-
tides or organic molecules that are carried into the cancer cell via
CPPs or full-length shuttling proteins.
The structures of many proteins have now been resolved owing
to the sequencing of the human genome. Furthermore, it is now
possible to fully characterize the interactions between many pro-
teins and their domains. Proteins bind into complexes specifically
with well-defined surfaces but also non-specifically through weak
Table 1
Selected examples of nuclear and mitochondrial CPP targeting of tumor cells in vivo.
Peptide Description
Nuclear targeting
buforin IIb buforin IIb accumulated in nuclei, induce mitochondria-dependent apoptosis with in vivo tumor suppression activity [237]
NLS-VP22 fusion of TmHU protein, NLS and VP22 transfected an immunogenic DNA vaccine in mice [238]
PF14 in vivo delivery of pDNA and tumor-specific gene induction by PF14 functionalized with PEG and a MMP substrate [112]
Tat, penetratin and
R11, NLS
CPP- and NLS-fused with APIM-consensus peptide targeted proliferating cell nuclear antigen, essential for DNA replication and repair in
multiple myeloma cell lines and primary cancer cells [239]
ETWW showed cellular and nuclear localization using an endocytic pathway and binding at the major groove of nuclear DNA in a spheroid model and
in vivo [240]
NLS NPY Tb159-NPY modified with a fatty acid, a cathepsin B-cleavable linker, NLS and a DOTA chelator, in nude mice bearing MCF-7 xenograft showed
tumor-specific uptake [241]
Mitochondrial targeting
MTD-DS43 mitochondrial targeting domain of Noxa protein, MTD, fused to DS43 showed anti-tumoral activity in mice with CT26 colon carcinoma [242]
TPP tumor penetrating peptide from oligomerization domain of Hsp70 was shown to be taken up via endosomes followed by co-localization with
mitochondrial membranes in tumors expressing Hsp70 [243]
iRGD procytotoxic peptide, m(KLA)-iRGD, internalized tumor cells, yielding mitochondrial-induced apoptosis and in tumor-bearing mice, a
significant reduction in tumor volume and inhibition of metastasis [244]
chol-FRFK/D nano-formulation of antimycin A, targeted to mitochondria and lung cancer by liposomes modified with Chol-FRFK/D [245]
Tat-PCC Tat modified propionyl-CoA carboxylase, a6b6 PCC, was delivered into mitochondria in vitro, in situ, and in vivo [246]
CAMP-hMT1A CAMP, conjugated with human metallothionein 1A, hMT1A localized to mitochondria in a mouse model of PD, rescued movement
impairment and dopaminergic neuronal degeneration [247]
Pep-1 whole mitochondria, conjugated with Pep-1 (P-Mito) showed decrease of transplant-induced growth inhibition, suggesting antitumor
potential [248]
Mito-ff Mito-ff, a mitochondria penetrating tripeptide showed mitochondrial disruption both in vitro and in vivo [249]
R8 R8-MTS (ALD5MTS), conjugated to doxorubicin, showed mitochondrial disruption and inhibition of tumor growth in 4 T1-bearing mice in vivo
[250]
Tat Tat-conjugated short peptides from calpain-1 C2-like domain inhibited mitochondrial calpain-1 and prevented neurodegenerative diseases of
the eye [251]
MPP (CFxrFxKFxrFxK) concurrent impairment of nucleus and mitochondria was shown to express anti-tumor and anti-metastatic effects by using MPP-Dox-loaded
HPMA copolymer, inhibiting lung tumor metastasis by damaging mitochondria/nucleus of breast cancer 4 T1 cells in vivo [252]
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affect protein–protein interactions by designing peptides and short
proteins that mimic the interactions between both intracellular
and extracellular proteins, thus modifying cellular function and
dynamics [115]. These intervening structures, usually peptides,
can arise from the sequences of natural proteins and their stability
can be enhanced by suitable modifications. Mimetic peptides usu-
ally bind to partner proteins and in this way block protein–protein
interactions; they are mostly inhibitors of interactions but in
rather rare cases they can also be activators of the partner protein
[116]. They are often detected by combinatorial screening meth-
ods, for instance by phage display, synthetic peptide libraries or
in silico molecular modeling [117]. A challenging problem is repli-
cation of the correct active fold, a matter of protein dynamics and
induced fit processes. The vast majority of protein mimics (small
organic molecules or peptides) known today have been designed
to inhibit the activity of oncogenes or activate tumor suppressors
[117]. If mimicking peptides are not able to penetrate cells, their
bioavailability to the cell interior is often facilitated by conjugation
to CPPs.
5.1. Protein mimics with CPP properties
It is desirable for a mimetic peptide to include in its structure
(sequence) the ability to bind to its protein partner, whilst possess-
ing effective CPP translocation properties. The term ‘‘bioportide”
was pioneered by the Howl group, to characterize CPPs with bioac-
tivity and distinguish them from the more classical biologically
inert vectors [118]. It was shown that positively charged protein
helices can be frequently used as a starting point to obtain
bioportides with mimetic properties [119]. Examples are the pep-
tides Cyt c86–101 and Cyt c77–101, representing helical domains of
Cytochrome c and mimicking its function [120]. These protein
mimicking CPPs could be of potential clinical utility in cancer
therapy.7
A number of peptides with CPP properties have recently been
identified which affect the development and propagation of cancer
tissue, see Table 2. Earlier examples are peptides from the tumor
suppressor protein p14ARF which bind to HDM2 [121], e.g. ARF1-22
[48]; SERPINA5, a protein C inhibitor (PCI) [122–124]; a cyclic CPP
constructed from a component of the histone H3 tail [125].
To inhibit the growth of cancer cells, inhibition of the p53/
HDM2 interaction has been used [126], exemplified by a helix-
loop-helix cyclic peptide that was constructed by combining a
p53 epitope in one helix and the R6 peptide with CPP properties
in the adjacent helix; a vascin (an amyloid peptide, based on an
amyloidogenic fragment of vascular VEGFR2 [127]; p28 entering
cancer cells, binding to p53 and restoring its functionality [128];
reactivation of p53 achieved by short peptide inhibitors of
MDM2 and MDMX proteins with cell-penetrant properties [129];
peptide inhibitors of p53-MDM2/MDMX and beta-catenin-Bcl9
interactions in vitro and in vivo [130]; the LinkTer peptide, derived
from the intrinsically disordered region (IDR) of p53 (289–322)
[131].
Additional examples include the following (Table 2) : stapled
peptide with high affinity for the estrogen receptor (R4K1) [132];
a CPP encompassing the PCNA (proliferating cell nuclear antigen)
interacting motif APIM [133]; NEMO/IKKb interaction inhibition
by bicyclic peptides [134]; helical sulfono-c-AApeptides that
mimic the a-helical domain of BCL9 (B-cell CLL/lymphoma 9 pro-
tein) [135]; vinylphosphonites were used for the inhibition of the
interaction between BCL9 and beta-catenin [136]; E4orf464-95,
named large adenodiaphorin or LadD64-95, inhibited the survival
of human U87G glioblastoma cells [137]; cTI (tachyplesin-I), a host
defense peptide from the horseshoe crab Tachypleus tridentatus
[138]; Anionic and proteolytically stable roseltide (rT7 [139]; the
Ser/Thr kinase CK2 targeting using CK2b-mimicking cyclic peptides
to modify the CK2a/CK2b interaction [140]; Mut3DPT-PP2A/SET
peptide blocked the interaction between the Ser/Thr phosphatase
PP2A and its oncogenic inhibitory binding partner SET [141];
Table 2
Selected protein mimics with CPP properties, relevant for cancer. The presented protein fragments demonstrate CPP properties as well as mimic/inhibit the source protein.
Protein source Description
Cyt c Cyt c86–101 and Cyt c77–101, helical domains of Cytochrome c mimicking its function [120]
p14ARF ARF1-22 restricts the proliferation of different cancer cells by mimicking the p14ARF protein [48].
p53-binding protein 2 CDB3 stabilized p53 following cellular internalization in vitro [253], potentially useful as a cancer treatment
PCI PCI1-11 and PCI1-18 are effective CPPs which can transport the entire protein into cells [124]
histone H3 tail cyclic CPP containing three-times methylated Lys and Tat, internalizes into cells and binds to histone demethylase PHF8
causing its subsequent inhibition [125]
p53 inhibition of p53/HDM2 interaction with a helix-loop-helix cyclic peptide combining a p53 epitope and R6 peptide with
CPP properties [126]
VEGFR2 vascin, amyloidogenic fragment of vascular VEGFR2, inhibited VEGFR2-dependent tumor growth in a tumor mouse
model [127]
p53 p28 binds to p53 and restores its functionality [128]
inhibitors of MDM2 and MDMX stapled peptides with high affinity for the estrogen receptor suppressed estrogen positive breast cancer [129]
NFjB NEMO/IKKb interaction was inhibited by bicyclic peptides in which one ring represented a motif for binding to the NFjB
modulator (NEMO) whilst the other ring displayed motives pertaining to various CPPs, inhibiting the proliferation of
ovarian cancer cells [134]
peptide inhibitors of p53-MDM2/MDMX
and Bcl9 interactions
blocked the interactions between p53 and MDM2/MDMX in the cytoplasm and between b-catenin and Bcl9 in the
nucleus, yielding potent inhibition of tumor growth and metastasis in vitro and in vivo [130]
BCL9 the mimic the a-helical domain of BCL9 (B-cell CLL/lymphoma 9 protein) disrupted b-catenin/BCL9 interactions after
entering cancer cells [135]
E4orf4 E4orf464-95 (large adenodiaphorin or LadD64-95) inhibited survival of human U87G glioblastoma cells [137]
j-casein RL2 (121 aa) showed cellular uptake into human cancer cells and the consequential antitumor activity [254]
omomyc omomyc (91 aa) enters cells and nuclei as omomyc/MYC and omomyc/MAX heterodimers and promotes displacement of
oncogenic MYC from its genomic location, yielding the transcriptional reprogramming of cancer cells [255]
tachyplesin-I cTI, a host defense peptide from the horseshoe crab Tachypleus tridentatus showed anticancer properties and cellular
uptake in melanoma cells [138]
roseltide (rT7) rT7 exhibited cellular penetration and inhibition of proteasomal activities, suggesting the potential in both anti-cancer or
anti-inflammatory therapies [139]
CK2 (Ser/Thr kinase) CK2b-mimicking cyclic peptides modify the CK2a/CK2b interaction showing cytotoxicity toward cancerous HeLa cells
[140]
p53 LinkTer peptide, p53(289–322) target a partner IDR from the anti-apoptotic iASPP proteinand promoted apoptosisin p53-
WT human cancer cells [131]
Mut3DPT-PP2A/SET peptide the peptide blocked the interaction between the Ser/Thr phosphatase PP2A and its oncogenic inhibitory binding partner
SET and reduced tumor size in vivo using breast UNLP-C3H/S tumor cells grafted into mice [141]
APIM, bacterial DNA sliding b-clamp APIM-derived peptides, ATX-101, demonstrated both antibacterial and anti-mutagenic activities [256]
Grb7 (growth factor receptor
bound protein 7)
Myristoylated and non-myristoylated peptides based on the calmodulin binding site of Grb7 inhibited proliferation,
migration and invasiveness of A431 tumor cells [142]
protein kinase B (PKB) FCHO1560-571, from the PKB substrate motif of human FCH domain only 1, following penetration, inhibited proliferation
via PKB/ERK/SMAD4 pathways in KRAS-mutated A549 lung cancer cells and suppressed tumor growth and decreased the
size and weight of tumors in A549-xenograft mice [143]
Ras protein sC18 showed cellular uptake and interaction with intracellular prenyltransferases as well as modulating downstream
signaling of Ras proteins, particularly K-Ras-4B, in pancreatic cancer cells [144]
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tor receptor bound protein 7) [142]; FCHO1560-571 from the PKB
substrate motif of human FCH domain only 1 [143]; sC18, bearing
a C-terminal CaaX prenylation motif based on Ras sequences [144].
A number of proteins have the ability to ‘‘travel” along DNA
[145,146], most of them by sliding on the DNA major groove,
which is contacted and recognized by stable a-helical protein
structures, 20–60 amino acids long. These sequences can be iden-
tified and separately synthesized, representing sliding protein
mimics. Sliding proteins affect DNA metabolism and gene regula-
tion [145,146]. Sliding molecules (sledges) [147,148] are defined
as ‘‘small basic molecules such as peptides that bind and slide
along DNA and can translocate cargo, for example a protein mole-
cule, along DNA”. This definition can also include cationic CPPs,
such as Tat [149] which also travel along DNA. More than 10 000
sled motifs have been predicted using both human and mouse pro-
teomes [149]. It is expected that many CPPs have DNA sliding abil-
ities, a feature that can be used for many different applications,
including cancer treatment.
The discovery that short fragments in protein sequences could
be used as protein mimics provided a breakthrough in the develop-
ment of novel pharmacological strategies Our understanding today
is that it is easy to find CPP sequences in natural proteins, which
can be facilitated using currently available prediction algorithms.
However, it is more difficult to locate amino acid sequences which
possess the dual/overlapping pharmacophores for both8
penetration and protein mimicry. such prediction algorithms were
to be developed, cell penetrating protein mimics with high target
specificity could soon become a new reality for pharmacology
and drug development. The above examples clearly suggest that
such an approach is indeed possible, particularly when targeting
some of the most poignant intracellular signaling pathways inte-
gral to cancer.
5.2. Delivery of protein mimics as cargos by CPPs
As discussed in several reviews [117,118], peptides have been
utilized to interfere with protein–protein interactions in cancer
cells. To gain highly effective access to the interior of cancer cells,
they have been fused to CPPs, most commonly to Tat, penetratin
and different polyarginines such as R11, and R9 [117,118]. In most
cases, mimicking peptides are the inhibitors of protein–protein
interactions and they are used to decrease tumor cell progression.
In the following section of this review, additional and more recent
examples will be presented, see Table 3.
Multiple examples of CPP-conjugated protein mimics include
many CPPs in combination with many short peptide mimics of
the targeted interface between proteins integral to cancer intracel-
lular signaling pathways, constructs that ultimately lead to cancer
cell death. To name a few examples from Table 3, the following
mimics can be selected : DOCK2-specific inhibitor [150]; sequence
derived from the BRC2 tumor suppressor protein [151]; inhibitory
Table 3
Selected examples of delivery of protein mimics or inhibitors as cargos by CPPs.
Protein mimic or target CPP Description
DOCK2-specific inhibitor CPP CPP-DOCK2-specific inhibitor of DOCK2/Rac interaction inhibited lymphocytes in the human
MINO cell line [150]
derived from BRC2 tumor suppressor
protein
R9 R9-coupled BRC2 tumor suppressor protein-derived peptide (BRC4) reduced DNA damage
promoted by the RAD51 protein, demonstrating potential in treatment of cancer [151]
inhibitory peptide of OGT penetratin, Tat CPP-inhibitory peptide of OGT (O-GlcNAc transferase) inhibited OGT resulting in a decrease in
breast cancer cell proliferation [152]
CtBPs, transcriptional co-repressor,
carboxy-terminal binding protein
Tat, Pep-1 inhibitor of CtBPs fused with CPP entered tumor cells, bound to CtBPs and prevented interaction
with partner proteins [153]
NF-jB inhibition CB5005 CPP-PEGylated liposomes showed NF-jB inhibition, delivered doxorubicin into intracranial
glioblastoma in animal models, and synergised the killing of glioma cells compared to
doxorubicin-loaded liposomes alone [257]
annexin A1 CPP CPP-ANXA120–30 and -ANXA128–30 (annexin A1-derived) blocked binding of annexin to the
receptor tyrosine kinase EphA2, targeting its degradation with a consequential suppression in
the growth of gastric cancer and colon cancer cells, in vitro and in mice [154]
SMAC (second mitochondria-derived
activator of caspases)
penetratin, Tat CPP-SMAC protein-derived peptides [155,156] showed antitumor activity
CIP1 (a cyclin-dependent kinase
inhibitor)
P21 p21WAF1/CIP1 showed antitumor activity [157]
ErbB2 targeting peptide Tat anErbB2 targeting peptide showed antitumor activity [158]
proapoptotic peptide Tat P15 (a proapoptotic peptide) showed antitumor activity [159],
p53 Tat peptide derived from the C-terminal of p53 showed antitumor activity [160]
NKp44 R11, NLS R11-NLS-pep8 decreased viability of different cancer cell lines and decreased tumor growth
in vivo [161]
TRAIL, a protein related to TNF R8 R8-TRAIL hindered tumor growth in vitro and in vivo [162]
Inhibition of phosphodiesterase 8A/
C-Raf complex
CPP PPL-008 was used to inhibited the complex in a melanoma cell line and in a melanoma
xenograft mouse model, showing tumor tissue labeling [163]
transcription factors CPP, NLS interfering peptide blocked the interaction between two transcription factors involved in the
Hippo signaling pathway TEAD and YAP, showed an anti-tumoral effect in xenograft models of
breast cancer [164]
anticancer peptide domain iRGD iRGD-HPRP-A1 showed tumor-targeting and tumor-penetrating activities by binding to the
neuropilin-1 receptor, killing cancer cells by disrupting the cell membrane and inducing
apoptosis in vitro and in vivo [165]
MDM2 cHLH cHLH-p53-R binds MDM2, showing toxicity towards cancer cells by its ability to selectively
target, cross, and disrupt cancer cell membranes [166]
HKII and the mitochondrial channel,
VDAC1
Pal-pHK-pKV Pal-pHK-pKV-HKII (N-terminus of hexokinase-II) enhanced apoptosis by perturbing the
interaction between HKII and VDAC1 showed mitochondrial colocalization in human non-small
cell lung cancer A549 cells, accompanied by substantial cell death [258]
ASH2L Tat Tat- ASH2L peptides, bind and inhibit DPY30 activity, inhibiting the growth of MLL-rearranged
leukemia and other MYC-dependent hematologic cancer cells [167]
ASF1 (conserved H3-H4 histone
chaperone) peptide inhibitors
Tat Tat-ip3 and -ip4 (ASF1 peptide inhibitors) showed uptake into U2OS cells, inhibition of the
ASF1-histone interaction and inhibition of tumor growth in mouse allografts [168]




peptides targeting the SH2 domain of Grb7, showed bioactivity as inhibitors of Grb7 [169]
tumor suppressor connexin43 Tat Tat-Cx43266-283 mimic the effect of connexin43 and inhibits the proto-oncogene c-Src,
intraperitoneal delivery decreased the invasion of intracranial tumors generated by GL261
mouse glioma cells in immunocompetent mice [170]




Tat-Cx43266-283 inhibited the activity of oncogenic Src and lead to disruption of EGF and FGF-2
signaling and down-regulation of b-catenin during gliomagenesis [178]
TX-101 (proliferating cell nuclear
antigen PCNA motif)




R9 R9-caPeptide disrupted PCNA-protein interactions in pancreatic cancer cells, causing lethal
DNA damage [175]
Cdc42-binding peptide R9 R9-Cdc42-binding peptide modulated specificity for small GTPases in Ras-driven cancer cell
models [171]
derived from inner centromere
protein INCENP, targeting survivin




Tat Tat-Trp2180-188 activated melanoma-specific immunity [173]
pro-apoptotic peptide sIL-24 NGR NGR-sIL-24 showed binding and cellular uptake of sIL-24 in U937 and A549 cancer cells
accompanied by inhibition of cell growth [174]
lipid-mimicking peptide Pm45 RGD RGD-Pm45 intercalated into lipid bilayers of erythrocyte vesicles and killed integrin avb3-
expressing MDA-MB-231 breast cancer cells in vitro and enhanced the therapeutic effects of
encapsulated doxorubicin in an MDA-MB-231 mouse xenograft model [260]
inhibitor of the MDM2/p53
interaction
Tat Tat-S100A1inhibited cell proliferation and induced cell cycle arrest at the G2/M phase [176]
Inhibitor of the activation of NFjB SynB1 SynB1-ELP1-p50 (NLS-derived peptide that inhibits the activation of NFjB) showed inhibition
of proliferation and induction of apoptosis in breast cancer cells [177]
c-myc inhibitor peptide H1 PNDD, short form of the
Pseudomonas Exotoxin w.
Tat, pVEC, penetratin
PNDD-mediated delivery of the c-myc inhibitor peptide H1, attenuaing cell proliferation and
inducing cell death in various tumor cell lines [261]
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(transcriptional co-repressors, carboxy-terminal binding protein)
[153]; CPP-conjugated annexin A1-derived ANXA120–30 and
ANXA128–30 [154].
Most of the mimicking peptides are derived from inhibitory
proteins, but some activating mimicks are also known. Therefore,
activation and inhibitory effects can be combined. However, to
achieve entrance into the cells mimicking peptides or proteins
are combined with CPPs, most often with penetratin or Tat. Older
examples are typified by the SMAC protein-derived peptides
(SMAC; second mitochondria-derived activator of caspases)
attached to Penetratin [155] or Tat [156], as well as p21WAF1/
CIP1 (a cyclin-dependent kinase inhibitor) [157], an ErbB2 target-
ing peptide [158], P15 (a proapoptotic peptide) [159], and a pep-
tide derived from the C-terminal of p53 [160], all fused to the
CPP Tat, bar the latter peptide mimic which uitilized multiple CPPs.
All of these constructs showed antitumor activity, for some of them
this was also demonstrated in vivo.
More recent examples include : R11-NLS-pep8 (EASALV-
CIRLVTSSKPRTVA, derived from NKp44) [161]; TRAIL, a protein
related to TNF [162]; inhibitor of phosphodiesterase 8A - C-Raf
complex [163]; a chimeric tri-functional peptide composed of
Mut7 DPT, NLS and an interfering peptide [164]; anticancer pep-
tide domain HPRP-A1 [165]; peptide cHLH-p53-R with high affin-
ity for MDM2, [166]; Tat-conjugated peptides, derived from
ASH2L which bind DPY30 [167]; Tat-modified ip3 and ip4 (ASF1
peptide inhibitors) [168]; penetratin-modified bicyclic peptides
targeting the SH2 domain of Grb7 [169]; Tat-Cx43266-283 mimick-
ing the effect of the tumor suppressor connexin43 and inhibit
the proto-oncogene c-Src [170]; R9-modified 16-mer cyclic
Cdc42-binding peptide [171]; R9-linked INC peptides (inner cen-
tromere protein INCENP-derived) [172]; tyrosinase-related protein
2-derived Trp2180-188 [173]; pro-apoptotic peptide sIL-24 with an
NGR (Asp-Gly-Arg) motif as a CD13-targeting component [174];
R9-caPeptide (PCNA126-133, mimicking proliferating cell nuclear
antigen) [175]; Tat-S100A1, designed to inhibit the MDM2/p53
protein–protein interaction [176]; thermally responsive SynB1-
ELP1 that inhibits the activation of NFjB [177]; Tat-Cx43266-283,
the Src-inhibitory sequence of the gap junction protein connexin43
[178].
The conjugation of CPPs with protein-derived mimics was a nat-
ural step in development of cell-penetrating influencers of pro-
tein–protein interactions. If the short protein-derived active
mimic cannot be turned into a CPP (cf. above), it has been natural
to connect it with a known CPP. Above it has been shown that this
strategy has been successful in vitro and in vivo.5.3. Antibody delivery and immune detection in cancer
Several examples are available where the immune response of
tumor cells is studied after treatment of cells or animals with dif-
ferent CPPs or CPP/cargo conjugates. Multiple CPPs (TP10, Pep-
Fects, Tat, stearyl-(RxR)4) were found to be nontoxic and
nonimmunogenic in vitro and in vivo [179]. For example, the Tat-
OVA protein induced antigen specific cytotoxic lymphocytes
[180], penetratin-OVA induced in vivo an immune response
against OVA expressing tumor cells [181,182], the Tat-Her2/neu
(human epidermal growth factor receptor 2) induced tumor-
specific T-cell responses in an in vivo murine breast tumor model
[183], pirarubicin coinjected with iRGD significantly improved
immune status of breast cancer bearing mice [184]. This suggests
opportunities for the use of CPP systems in immune-based detec-
tion and imaging of cancer mechanisms. Additionally, CPP-
antigen conjugates have been used in CPP based vaccinations
in vivo as well as for cancer immunotherapy [185–193].10The CPP-protein conjugation by fusion seems to be a fruitful
strategy for the creation of cell transducing proteins, several
attempts can be found for antibody and antigen delivery [194–
198]. Examples include several antibody or antibody fragment
delivery systems, e.g. Tat-SpA (staphylococcal protein A) fusion
protein, mixed with Fl-IgG was observed intracellularly
[199,200], 9D11-Tat-antibody targeting hepatitis B virus X protein
significantly suppressed viral transcription, replication, and pro-
tein production both in vitro and in vivo [201], Pep-1-, PEPth-
antibody targeting cancer cells reached the cytosol of LS174T cells
[202], R9-HuscFvs transbodies entered enterovirus-infected cells
[203], CPP-transbodies, -HuscFvs showed anti-HIV-1 activity
[204], CPP (R9, penetratin, Tat and hLF)-EGFR-binding nanobody
7D12 induced endocytosis [205]. Additionally, CPP-‘‘flashbodies”
(antibody probe connected with antigen-dependent fluorescence
intensity) showed cell internalization [206].
Chemical conjugation of CPPs with Abs or their fragments,
yielding cellular or tumor uptake has been reported, e.g. Tat(44–
57)-Cys-scFv(L19) [207], transportan-GFP and -ABs, [208], Cys-
THIOMAB antibody-drug-penetratin in mouse tumor xenografts
[209], mAbs (matuzumab, trastuzumab and ADC Kadcyla) conju-
gated to tetrameric CPPs showed internalization into A431 cells
and in mice bearing A431 xenografts [210], cR10-TAMRA, -anti-
GFP nanobody GBP1, -NLS-mCherry, functional enzymes, nanobod-
ies and full-length immunoglobulin-G antibodies showed cytoso-
lic/nuclear delivery in HeLa Kyoto cells via endocytosis and
endosomal escape or by directly transducing the membrane
[211]. AB fragment (RAD51, a protein involved in homologous
recombination DNA repair), inhibited RAD51 ssDNA binding
in vitro when fused to iPTD [212].
Biotinyl-CPP conjugates between avidin- and biotin (or avidin-
and biotin-modified Abs), have been widely used in studies of CPP
mechanisms and detection and a few examples are highlighted
below, most carried out with different cancer cell lines. Intracellu-
lar N-e13-biotinyl-transportan was visualized by indirect
immunofluorescence after permeabilization of Bowes’ cells with
methanol and adding of streptavidin-FITC or streptavidin-Texas
red; the role of non-endocytotic uptake was suggested [6]. Later,
the biotinyl-transportan was used for visualization of cellular
delivery and localization of anti-biotin monoclonal antibodies
[208]. An Na-Biotinyl-TP10/Fl-streptavidin complex was used in
the report on photo-induced endosomal escape of CPP-SA [213].
Complexed with avidin biotinyl-penetratin, -Tat, transportan, and
-pVEC were shown to use the endocytotic, clathrin-dependent
and independent mechanism of the protein cellular transduction
[214]. Deleted sentence
Complexation of CPPs/Abs has been reported in but a few
cases. CPPs from the spider Mlycotoxin with encapsulated anti-
bodies (IgGs) showed cellular uptake by inducing macropinocyto-
sis [215]. A sorbitol-based molecular carrier with 8 guanidine
units (Sor-G8) was used for intracellular and transdermal delivery
of proteins (GFP, albumin, concanavalin A, and IgG) though after
complexing, was more efficient than R8 complexes [216]. [216].
CPP mimic-Abs for protein kinase C theta showed delivery into pri-
mary human CD4 T cells in a humanized mouse model [217]. How-
ever, R6/bevacizumab, administered using eye drops had no effect
on increasing desired biological stability and increased aggregation
[218].
Targeting proteinswith CPPs been achieved by conjugated Abs.
Antibody targeted triggered electrically modified prodrug type
strategy, ATTEMPTS [219] uses ‘‘non-covalent conjugation of tar-
geting antibodies linked to heparin and CPP linked to the protein
drug”, which releases the CPP-drug complex for specific internal-
ization into specific antibody-targeted tumor cells [219], This stat-
egy has demonstrated potential for colorectal cancer therapy [220],
and for the treatment of acute lymphoblastic leukemia.
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CPPs
Chemotherapy is used to suppress tumor growth and the meta-
static proliferation of cancer. The cytostatic action of different
agents has greatly improved survival prognosis. However, this is
marred by many undesirable side effects owing to the inherent
lack of tumor cell specificity of chemotherapeutics and their subse-
quent deleterious effects on healthy tissue. Selective delivery of
chemotherapeutics into cancer cells is a long-term goal for which
delivery by tumor targeting CPPs could be of great benefit. Since
no CPP has yet to be approved for clinical use, we shall only present
experimental results with the most frequently used cytostatic
agents, doxorubicin, methotrexate, and paclitaxel.6.1. Doxorubicin (DOX)
Doxorubicin is commonly used as a cytostatic but it generally
induces tumor cell resistance. To avoid this, DOX was simultane-
ously coupled to penetratin and Tat [221]. The constructs were
shown to be internalized by several drug sensitive and drug resis-
tant cancer cells with increased cytotoxicity. The same group has
further observed that mitochondrial disruption is the main mech-
anism in DOX-induced apoptotic signaling, however DOX–CPPs are
probably able to trigger additional apoptotic pathways indepen-
dent of mitochondrial events [222]. Another group investigated
the influence of different CPPs (Tat, penetratin and mastoparan),
on the transport of DOX encapsulating transferrin (Tf) liposomes
across the brain endothelial barrier, in vitro and in vivo [223]. They
observed efficient translocation of anticancer drug-loaded Tf-CPP
liposomes across the brain endothelial barrier, demonstrating that
CPP-mediated transport across the restrictive blood–brain barrier
is indeed possible. Recently, such combined delivery of DOX with
different nanocarriers has undergone extensive study. In one study,
reversibly crosslinked hybrid micelles (RCMs) were engineered
based on the CPP Tat, tocopherol PEG -succinate and PEG-b-poly
(aspartic-lipoic acid). RCMs loaded with DOX behaved as pH sensi-
tive drug delivery vectors and DOX successfully accumulated in
cancer cells [224]. Another recent example is the construction of
Asp-Gly-Arg peptide (NGR)-modified nanobubbles (NBs) contain-
ing CPP-decorated DOX and CPP-decorated c-myc-siRNA [225].
By this procedure encapsulation efficiencies of DOX exceeded
80%. Release of DOX could be triggered by ultrasound since above
80% DOX was released from NBs after sonication while less than 5%
DOX was discharged in the absence of ultrasound.6.2. Methotrexate (MTX)
One of the first demonstrations that CPPs can successfully be
used to deliver cytostatics into a drug resistant cell model was
by Lindgren and co-workers[101]. They constructed two different
CPPs, YTA2 and YTA4, and monitored the intracellular delivery of
MTX to MTX-resistant breast cancer cells MDA-MB-231 by fluores-
cence microscopy and quantitative fluorometry. It was shown that
MTX-CPP constructs entered and destroyed cells more efficiently
than MTX alone, despite MTX resistance. The same group later cou-
pled MTX to a matrix metalloproteinase-activatable tumor target-
ing CPP, named NoPe, a modification of YTA4. Following
intravenous injection, they showed selective accumulation of the
cargo in tumor tissue of MDA-MB-231 tumor bearing mice [226].
Other groups have selectively delivered MTX or its modified struc-
ture to cancer tissue and have used CPPs such as polyarginine or
penetratin [227] or the selective cell penetrating peptide
(RLWMRWYSPRTRAYGC) coupled to functionalized polymersomes
(construct abbreviated SCPP-PS) for the targeting of human lung11cancer in vivo [228], in addition to utilizing numerous other CPPs
[229].6.3. Paclitaxel (PTX)
PTX is a first-line chemotherapeutic that has proven efficacy
against many solid tumors. However, it exhibits several application
problems due to its poor solubility, low membrane permeability
and lack of cancer cell selectivity. To minimize these problems, a
‘‘smart” peptide-drug conjugate was constructed, by linking PTX
with a multifunctional peptide consisting of a tumor targeting pep-
tide (TTP) and a CPP [230]. This novel construct, TTP-CPP-PTX, was
called LTP-1. It could deliver PTX into LHRH receptor-
overexpressing MCF-7 cancer cells, demonstrating an approxi-
mately two-fold higher degree of cellular uptake compared to
PTX alone. LTP-1-induced cytotoxicity was also enhanced, giving
an IC50 of 3.8 nM compared to 6.6 nM for PTX alone. Encouragingly,
LTP-1 exhibited less cytotoxicity towards normal cells and an abil-
ity to overcome PTX-resistance. In another study, the tumor hom-
ing CPP tLyP-1 was fused to the N-terminal of human H chain
ferritin (HFtn) and PTX molecules were encapsulated into an HFtn
nanocage [231]. These nanoparticles were tested for cytotoxicity
against MDA-MB-231 and SMMC-7721 tumor cells in vitro and
in vivo (in mice). It was demonstrated that the tLyP-1-HFtn-PTX
nanoparticles selectively accumulated within and penetrated
tumor regions. Verified by the breast cancer cell model in BABL/c
nude mice, tLyP-1-HFtn-PTX displayed higher in vivo therapeutic
efficacy with lower systemic toxicity. Another group [232] first
used a dual-functional polyarginine CPP R7 for delivery of PTX
but because of the unstable noncovalent bond between R7 and
PTX, a novel positive CPP carrier of P9 was developed to improve
CPP-PTX affinity via a double-proline hairpin tail. This new con-
struct, as it was shown, can quickly translocate into the HeLa cells
within 1 min and exhibits no noticeable cytotoxicity, eventually
resulting in a significant reduction in tumor cell viability. The con-
struct was also tested in vivo, demonstrating that the P9-PTX com-
plex dramatically inhibits tumor growth.
Collectively, these experiments endorse coupling of chemother-
apeutic agents to CPPs in order to achieve a more effective delivery
of cytostatic drugs to tumor cells, with fewer side effects and
reduced damage to normal healthy tissue.7. Conclusions
Peptides hold great potential for cancer therapy and diagnos-
tics. CPPs have been used extensively as delivery vectors for intra-
cellular and trans-barrier delivery of multiple bioactive cargos,
including protein mimics (short, natural protein-derived peptides)
which can either be conjugated to CPPs or used independently
owing to intrinsic cellular translocation properties. Such ‘‘perme-
able” protein mimics are usually designed to either enhance or
inhibit certain defined routes of intracellular signaling. Specific tar-
geting of different cancer types has been achieved with a remark-
ably high number of examples, such as using tumor-homing
sequences, or triggering pro-drug activation by pH, hypoxia or dif-
ferent enzymes. This review clearly summarizes suggestions for
the future applications of biobarrier-passing and peptide-based
strategies in cancer therapy and diagnostics.Funding
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